Complement component 3 is a prognostic factor of non-small cell lung cancer

Molecular Medicine Reports

Volumn 10, Issue 2, 2014, Pages 811-817

  Lin, Kailong ^a   He, Siyi ^a   He, Luhang ^a   Chen, Junyin ^a   Cheng, Xiaoming ^a   Zhang, Guoqiang ^a   Zhu, Bo ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Cancer related inflammation; Complement component C3; Lymphocyte infiltration; Non small cell lung cancer; Prognostic factor

Indexed keywords

CD8 ANTIGEN; COMPLEMENT COMPONENT C3;

ADULT; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG BIOPSY; LUNG LESION; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OVERALL SURVIVAL; SEX DIFFERENCE; SMOKING; T LYMPHOCYTE; AGED; CARCINOMA, NON-SMALL-CELL LUNG; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CYTOLOGY; IMMUNOLOGY; KAPLAN MEIER METHOD; LUNG NEOPLASMS; METABOLISM; MORTALITY; PATHOLOGY; PROGNOSIS;

AGED; CARCINOMA, NON-SMALL-CELL LUNG; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; COMPLEMENT C3; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS;

EID: 84903313565     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2014.2230     Document Type: Article

References (33)

1. Martin J and Rusch V: Lung neoplasms. In: Surgery: Scientific Principles and Clinical Practice. Greenfield L, Mullholland M, Oldham K, Zelenock G and Lillemoe K (eds). Lippincott Williams and Wilkins, Philadelphia, PA, pp1373-1400, 2001.
2. Sica A, Allavena P and Mantovani A: Cancer related inflammation: the macrophage connection. Cancer Lett 267: 204-215, 2008.
3. Kuang DM, Zhao Q, Peng C, Xu J, Zhang JP, Wu C and Zheng L: Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1. J Exp Med 206: 1327-1337, 2009.
4. Sica A and Bronte V: Altered macrophage differentiation and immune dysfunction in tumor development. J Clin Invest 117: 1155-1166, 2007. (Pubitemid 46718400)
5. Marigo I, Dolcetti L, Serafini P, Zanovello P and Bronte V: Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells. Immunol Rev 222: 162-179, 2008. (Pubitemid 351430364)
6. Haverkamp JM, Crist SA, Elzey BD, Cimen C and Ratliff TL: In vivo suppressive function of myeloid-derived suppressor cells is limited to the inflammatory site. Eur J Immunol 41: 749-759, 2011.
7. Ikushima H and Miyazono K: TGFβ signalling: a complex web in cancer progression. Nat Rev Cancer 10: 415-424, 2010.
8. Calon A, Espinet E, Palomo-Ponce S, et al: Dependency of colorectal cancer on a TGF-beta-driven program in stromal cells for metastasis initiation. Cancer Cell 22: 571-584, 2012.
9. Sansone P and Bromberg J: Targeting the interleukin-6/Jak/stat pathway in human malignancies. J Clin Oncol 30: 1005-1014, 2012.
10. Maniati E, Soper R and Hagemann T: Up for Mischief? IL-17/Th17 in the tumour microenvironment. Oncogene 29: 5653-5662, 2010.
11. Donin N, Jurianz K, Ziporen L, Schultz S, Kirschfink M and Fishelson Z: Complement resistance of human carcinoma cells depends on membrane regulatory proteins, protein kinases and sialic acid. Clin Exp Immunol 131: 254-263, 2003. (Pubitemid 36205136)
12. Bubeck D, Roversi P, Donev R, Morgan BP, Llorca O and Lea SM: Structure of human complement C8, a precursor to membrane attack. J Mol Biol 405: 325-330, 2011.
13. Walport MJ: Complement. First of two parts. N Engl J Med 344: 1058-1066, 2001.
14. Walport MJ: Complement. Second of two parts. N Engl J Med 344: 1140-1144, 2001.
15. Boross P and Leusen JH: Boosting antibody therapy with complement. Blood 119: 5945-5947, 2012.
16. Ross GD, Vetvicka V, Yan J, Xia Y and Vetvicková J: Therapeutic intervention with complement and beta-glucan in cancer. Immunopharmacology 42: 61-74, 1999. (Pubitemid 29322289)
17. Markiewski MM, DeAngelis RA, Benencia F, et al: Modulation of the antitumor immune response by complement. Nat Immunol 9: 1225-1235, 2008.
18. Li F, Cheng Y, Lu J, Hu R, Wan Q and Feng H: Photodynamic therapy boosts anti-glioma immunity in mice: a dependence on the activities of T cells and complement C3. J Cell Biochem 112: 3035-3043, 2011.
19. Blok VT, Daha MR, Tijsma O, et al: A bispecific monoclonal antibody directed against both the membrane-bound complement regulator CD55 and the renal tumor-associated antigen G250 enhances C3 deposition and tumor cell lysis by complement. J Immunol 160: 3437-3443, 1998. (Pubitemid 28164737)
20. Oner F, Savaş I and Numanoǧlu N: Immunoglobulins and complement components in patients with lung cancer. Tuberk Toraks 52: 19-23, 2004.
21. Zimmermann-Nielsen E, Iversen LH, Svehag SE, Thorlacius-Ussing O and Baatrup G: Activation capacity of the alternative and classic complement pathways in patients operated on for colorectal cancer. Dis Colon Rectum 45: 544-553, 2002. (Pubitemid 34407734)
22. Saito T, Kuwahara A, Kinoshita T, et al: Increases in immunoglobulin and complement in patients with esophageal or gastric cancer. Surg Today 22: 537-542, 1992. (Pubitemid 23001055)
23. Espinosa E, Feliu J, Zamora P, et al: Serum albumin and other prognostic factors related to response and survival in patients with advanced non-small cell lung cancer. Lung Cancer 12: 67-76, 1995.
24. Takigawa N, Segawa Y, Okahara M, et al: Prognostic factors for patients with advanced non-small cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation. Lung Cancer 15: 67-77, 1996. (Pubitemid 26337010)
25. Yee J, Sadar MD, Sin DD, et al: Connective tissue-activating peptide III: a novel blood biomarker for early lung cancer detection. J Clin Oncol 27: 2787-2792, 2009.
26. Zhong L, Coe SP, Stromberg AJ, Khattar NH, Jett JR and Hirschowitz EA: Profiling tumor-associated antibodies for early detection of non-small cell lung cancer. J Thorac Oncol 1: 513-519, 2006. (Pubitemid 47181397)
27. Qiu J, Choi G, Li L, et al: Occurrence of autoantibodies to annexin I, 14-3-3 theta and LAMR1 in prediagnostic lung cancer sera. J Clin Oncol 26: 5060-5066, 2008.
28. Trinchieri G: Cancer and inflammation: an old intuition with rapidly evolving new concepts. Annu Rev Immunol 30: 677-706, 2012.
29. Lucas SD, Karlsson-Parra A, Nilsson B, et al: Tumor-specific deposition of immunoglobulin G and complement in papillary thyroid carcinoma. Hum Pathol 27: 1329-1335, 1996. (Pubitemid 26415328)
30. Blok VT, Daha MR, Tijsma OM, Weissglas MG, van den Broek LJ and Gorter A: A possible role of CD46 for the protection in vivo of human renal tumor cells from complement-mediated damage. Lab Invest 80: 335-344, 2000. (Pubitemid 30167793)
31. Varga L, Czink E, Miszlai Z, et al: Low activity of the classical complement pathway predicts short survival of patients with chronic lymphocytic leukaemia. Clin Exp Immunol 99: 112-116, 1995.
32. Klos A, Tenner AJ, Johswich KO, Ager RR, Reis ES and Köhl J: The role of the anaphylatoxins in health and disease. Mol Immunol 46: 2753-2766, 2009.
33. de Visser KE, Korets LV and Coussens LM: Early neoplastic progression is complement independent. Neoplasia 6: 768-776, 2004. (Pubitemid 40041495)